Calcium channel blockers (CCBs, non-dihydropyridine)
- Verapamil + diltiazem
- Slow AV-node conduction + lower HR
- Uses: SVT, AF rate control + angina
- Bradycardia/heart block can occur
- Avoid in significant HFrEF
- CYP3A/P-gp inhibition adds DDI burden
Class at a glance
- Verapamil + diltiazem
Clinical role
- Uses: SVT, AF rate control + angina
Pharmacology
- Bradycardia/heart block can occur
- CYP3A/P-gp inhibition adds DDI burden
Practical pearls
- Slow AV-node conduction + lower HR
Safety / monitoring
- Avoid in significant HFrEF
Self-check
- When should Calcium channel blockers (CCBs, non-dihydropyridine) generally be avoided?
Significant HFrEF. - What are the main clinical uses of Calcium channel blockers (CCBs, non-dihydropyridine)?
SVT, AF rate control + angina.
Drugs in this class (2)
Calcium channel blockers (CCBs, non-dihydropyridine) prescription history
Animated chart of estimated U.S. prescriptions per year, Calcium-channel blockers (1981–2026). Non-dihydropyridine highlighted from 1981.
All drug classes · Open Calcium channel blockers (CCBs, non-dihydropyridine) in the interactive console ↗